Enveric Biosciences (ENVB) director receives 18,518 restricted stock shares as equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kegler George A. reported acquisition or exercise transactions in this Form 4 filing.

Enveric Biosciences director George A. Kegler received a grant of 18,518 shares of restricted common stock on June 1, 2026 under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. The grant was awarded at $0.0000 per share as equity compensation.

After this award, Kegler directly holds 26,418 shares of Enveric Biosciences common stock. The restricted shares will vest over time in line with the terms of the 2020 Long-Term Incentive Plan and his restricted stock award agreement.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kegler George A.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	18,518	$0.00	--

Holdings After Transaction: Common Stock — 26,418 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Restricted stock grant: 18,518 shares Grant price per share: $0.0000 per share Shares held after grant: 26,418 shares

3 metrics

Restricted stock grant 18,518 shares Grant to director George A. Kegler on June 1, 2026

Grant price per share $0.0000 per share Stated price for restricted stock award

Shares held after grant 26,418 shares Total common stock directly owned by Kegler after transaction

Key Terms

restricted stock, 2020 Long-Term Incentive Plan, Form 4, Grant, award, or other acquisition

4 terms

restricted stock financial

"Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2020 Long-Term Incentive Plan financial

"pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 04:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kegler George A.

(Last)

(First)

(Middle)

245 FIRST STREET, RIVERVIEW II

18TH FLOOR

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enveric Biosciences, Inc. [ ENVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		A		18,518⁽¹⁾	A	$0	26,418	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

	/s/ George A. Kegler	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Enveric Biosciences (ENVB) report for George A. Kegler?

Enveric Biosciences reported that director George A. Kegler received 18,518 shares of restricted common stock as a grant. The award was made as equity compensation under the company’s 2020 Long-Term Incentive Plan, rather than being purchased in the open market.

How many Enveric Biosciences (ENVB) shares does George A. Kegler hold after this grant?

Following the grant, George A. Kegler directly holds 26,418 shares of Enveric Biosciences common stock. This total includes the newly granted 18,518 restricted shares, which will vest according to the plan and his restricted stock award agreement.

Was cash paid for the Enveric Biosciences (ENVB) restricted stock granted to George A. Kegler?

No cash was paid for the grant; the 18,518 restricted shares were awarded at a stated price of $0.0000 per share. This indicates a compensation grant rather than a market purchase, consistent with typical long-term incentive plan awards.

Under which plan was George A. Kegler’s Enveric Biosciences (ENVB) stock grant issued?

The restricted stock grant was issued under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. The footnote explains that vesting will follow the detailed terms of this plan and Kegler’s specific restricted stock award agreement.

How is the Enveric Biosciences (ENVB) restricted stock grant to George A. Kegler structured?

The grant consists of 18,518 restricted shares that vest over time under plan and award agreement terms. Until vesting conditions are met, the shares are subject to restrictions, which is standard for equity compensation to directors or executives.